Investors in Endo International (NASDAQ: ENDP) have seen the stock decimated by persistent declines in demand for prescription painkillers and nationwide opioid litigation. The company's spending on research and development has been less than its competitors' for years, but results may be on the horizon at last. Will the company's new Biologic License Application to treat cellulite in a billion-dollar market be able to reverse its fortune?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,